Literature DB >> 20498400

Wrestling with the high price of cancer care: should we control costs by individuals' ability to pay or society's willingness to pay?

Jennifer L Malin.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20498400     DOI： 10.1200/JCO.2010.28.9967

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  9 in total

1.  Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer.

Authors:  David R Lairson; Rohan C Parikh; Janice N Cormier; Wenyaw Chan; Xianglin L Du
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

2.  Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.

Authors:  Mahdi Gharaibeh; Ali McBride; David S Alberts; Brian Erstad; Marion Slack; Nimer Alsaid; J Lyle Bootman; Ivo Abraham
Journal:  Pharmacoeconomics       Date:  2018-11       Impact factor: 4.981

Review 3.  Financial Hardship--an Unwanted Consequence of Cancer Treatment.

Authors:  Julie McNulty; Nandita Khera
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

Review 4.  Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review.

Authors:  Daniel M Geynisman; Chun-Ru Chien; Fabrice Smieliauskas; Chan Shen; Ya-Chen Tina Shih
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 5.  Importance of cost-effectiveness and value in cancer care and healthcare policy.

Authors:  Ravinder Kang; Philip P Goodney; Sandra L Wong
Journal:  J Surg Oncol       Date:  2016-06-22       Impact factor: 3.454

6.  Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?

Authors:  Helmy M Guirgis
Journal:  J Oncol Pract       Date:  2012-07       Impact factor: 3.840

7.  The economic pressures for biosimilar drug use in cancer medicine.

Authors:  Paul Cornes
Journal:  Target Oncol       Date:  2012-01-17       Impact factor: 4.493

8.  Oncologists' and family physicians' views on value for money of cancer and congestive heart failure care.

Authors:  Dan Greenberg; Ariel Hammerman; Shlomo Vinker; Adi Shani; Yuval Yermiahu; Peter J Neumann
Journal:  Isr J Health Policy Res       Date:  2013-11-18

9.  Cost-effectiveness of the Collaborative Care to Preserve Performance in Cancer (COPE) trial tele-rehabilitation interventions for patients with advanced cancers.

Authors:  Colleen F Longacre; John A Nyman; Sue L Visscher; Bijan J Borah; Andrea L Cheville
Journal:  Cancer Med       Date:  2020-02-23       Impact factor: 4.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.